

**Table 4** Magnitude of efficacy in relation to different trough serum infliximab levels


	Trough serum infliximab level				<i>p</i> value (overall)
	<0.1 µg/ml	≥0.1 and <1.0 µg/ml	≥1.0 and <10 µg/ml	≥10 µg/ml	
<b>EULAR response</b>					
Total ( <i>n</i> = 271)	66 (100)	40 (100)	143 (100)	22 (100)	
No response ( <i>n</i> = 31)	21 (31.8)	8 (20.0)	2 (1.4)	0 (0.0)	
Moderate response ( <i>n</i> = 106)	31 (47.0)	20 (50.0)	50 (35.0)	5 (22.7)	<0.0001
Good response ( <i>n</i> = 134)	14 (21.2)	12 (30.0)	91 (63.6)	17 (77.3)	
<b>DAS28 remission</b>					
Total ( <i>n</i> = 271)	66 (100)	40 (100)	143 (100)	22 (100)	
No remission ( <i>n</i> = 182)	58 (87.9)	34 (85.0)	80 (55.9)	10 (45.5)	<0.0001
Remission ( <i>n</i> = 89)	8 (12.1)	6 (15.0)	63 (44.1)	12 (54.5)	
<b>Radiographic progression</b>					
Total ( <i>n</i> = 270)	65 (100)	40 (100)	143 (100)	22 (100)	
Progressed ( <i>n</i> = 23)	9 (13.8)	4 (10.0)	10 (7.0)	0 (0.0)	
No change ( <i>n</i> = 231)	56 (86.2)	33 (82.5)	122 (85.3)	20 (90.9)	0.0043
Improved ( <i>n</i> = 16)	0 (0.0)	3 (7.5)	11 (7.7)	2 (9.1)	

Values are the number (%) of patients

Blood samples were obtained at week 54. Serum infliximab levels were quantified by ELISA. Patients were grouped according to four different ranges of trough serum infliximab level as shown

Radiographic progression was categorized in change of total modified Sharp score as follows: progressed (>4.1), no change (≥−4.1 and ≤4.1), and improved (<−4.1)

**Fig. 4** Cumulative probability plot of the total modified Sharp score (TSS) in relation to trough serum infliximab level at week 54 in all patients (a, *n* = 270), and in early RA patients (b, *n* = 84). Patients were grouped according to four different ranges of trough serum infliximab levels as shown



discontinuation or serious infections also showed no significant difference. The main adverse events classified using the system organ classes (SOCs) were: laboratory tests (70.2–73.7%), infections and infestations (46.2–53.8%), and skin and subcutaneous tissue disorders (21.2–32.3%). The types of adverse events in the groups administered 6 and 10 mg/kg were similar to those in the 3 mg/kg group (data not shown). No patient died over the entire study period.

## Discussion

Some pivotal clinical studies, such as the ATTRACT study, have demonstrated that infliximab treatment brought

about a reduction in signs and symptoms, inhibition of the progression of joint damage, and improvement of physical function in patients with RA. It was reported that this treatment was very effective in Japanese RA patients [7, 22, 23]. However, it has been noted that infliximab is not sufficiently efficacious in some patients because the approved dosage is only 3 mg/kg every 8 weeks in Japan. The RISING study was performed to investigate the efficacy and safety of treatment of RA with infliximab, comparing 10 mg/kg with 3 mg/kg.

The ACR-N, the primary end point of this study, was 58.3% in the 10 mg/kg group and 51.3% in the 3 mg/kg group, representing a significant difference. In addition, as regards change in DAS28 and EULAR response criteria, significantly higher responses were observed in the 10 mg/kg

**Table 5** Incidence of adverse events (AEs)

	All periods (0–54 weeks)  ( <i>n</i> = 327)	Open-label period (0–14 weeks)  ( <i>n</i> = 327)	Double-blind period (14–54 weeks)		
			3 mg/kg ( <i>n</i> = 99)	6 mg/kg ( <i>n</i> = 104)	10 mg/kg ( <i>n</i> = 104)
Any AEs	319 (97.6)	242 (74.0)	97 (98.0)	97 (93.3)	101 (97.1)
Serious AEs <sup>a</sup>	38 (11.6)	17 (5.2)	7 (7.1)	5 (4.8)	9 (8.7)
AEs leading to discontinuation of study agents	39 (11.9)	19 (5.8)	7 (7.1)	9 (8.7)	5 (4.8)
Infections	230 (70.3)	124 (37.9)	56 (56.6)	57 (54.8)	67 (64.4)
Serious infections	17 (5.2)	7 (2.1)	3 (3.0)	2 (1.9)	5 (4.8)
Infections leading to discontinuation of study agents	12 (3.7)	6 (1.8)	3 (3.0)	3 (2.9)	0 (0.0)
Infusion reactions <sup>b</sup>	92 (28.1)	41 (12.5)	17 (17.2)	25 (24.0)	23 (22.1)
Serious infusion reactions	1 (0.3)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)

Values are the number (%) of patients

<sup>a</sup> Any AEs that resulted in any life-threatening events, inpatient hospitalizations, prolongation of existing hospitalization or significant disability/incapacity

<sup>b</sup> Any AEs that occurred during an infusion or within 2 h after completion of an infusion

group compared with the 3 mg/kg group. These results are the first evidence of better clinical responses at 10 mg/kg in comparison with 3 mg/kg in a double-blind study. This was possibly because we employed the ACR-N and DAS28 change, which indicate the magnitude of improvement, and the EULAR response, which reflects actual disease activity, whereas the ACR responses, which represent categorical criteria for improvement, were used in the ATTRACT study. In addition, when we focused on non-responders at 10 weeks, EULAR response rates at week 54 were significantly increased in the high-dose groups compared with those in 3 mg/kg group.

The ATTRACT trial and the Safety Trial for Rheumatoid Arthritis with Remicade (infliximab) Therapy (START) have already demonstrated a significant association between clinical response and trough serum infliximab level [24, 25]. In the RISING study, a significant correlation was observed between serum trough level and EULAR response or DAS28 remission. The median trough serum level at week 54 in EULAR nonresponders was <0.1 µg/ml, and that in EULAR responders (good or moderate response) was 1.1 µg/ml, which was consistent with that reported in the ATTRACT and START studies. This suggests that a trough serum level of 1.0 µg/ml is the threshold level for clinical response, as reported previously.

Infliximab treatment inhibited the progression of joint damage in most of patients regardless of infliximab dose in the RISING study. It is interesting to note that infliximab inhibited progression of joint damage even in patients receiving low dose of MTX. A significant correlation between progression or improvement of joint damage and trough serum infliximab level, which had not been

investigated sufficiently so far, was also shown, raising the possibility that joint damage might progress in patients with a low trough serum level. This correlation was more remarkable in early RA patients in whom joint destruction progresses rapidly. The factors that influenced the trough serum infliximab level were thought to be the serum clearance of infliximab as well as production of anti-infliximab antibodies [26]. This study showed the significant association between serum trough level and clinical responses or radiographic progression. It appears that anti-infliximab antibodies may be one of the important factors that influence the efficacies of infliximab therapy.

In the RISING study, the safety profile of the high-dose groups was similar to that of the 3 mg/kg group, and no significant difference was found in the incidence of adverse events or serious adverse events including infections. However, the START study showed that the incidence of serious infections in the 10 mg/kg group increased in the 22-week period after the start of treatment [5]. It was reported that bacterial pneumonia (a major serious infection) was commonly observed in the early phase of the treatment (until week 14) in the Japanese post-marketing surveillance (PMS) of 5,000 patients [27]. It should be noted that the three induction infusions at 0, 2, and 6 weeks in the RISING study used a 3 mg/kg dose for all three dosing groups, whereas in the previous reports the same dose was used throughout the entire study period, including the induction phase. The different dose in the induction phases of these studies might account for the different results regarding serious adverse events. It is very important to examine the association between trough serum infliximab level and safety. However, the time of occurrence of adverse events varied in every patient, and we did

not measure the serum level at week 54 in patients who discontinued infliximab treatment because of adverse events. Therefore, we were unable to investigate the association between them. If there is a significant association between infliximab serum level and safety, the efficacy should be higher in the discontinued patients than in the patients who continued with infliximab therapy because the efficacy is dependent on the infliximab level. However, the ACR-N in the discontinued patients before discontinuation was lower than that of the continued patients at week 54. This means that the serum infliximab level of the former patients was lower than that of the latter. Furthermore, no significant difference of the rate of adverse events or infections was observed between the 3, 6, and 10 mg/kg groups in this study. These results may indicate the possibility that serum trough infliximab level does not influence the safety of infliximab therapy. Further investigation on this matter is considered to be necessary.

The RISING study showed that infliximab treatment with 3 mg/kg resulted in a good clinical response in many patients, while treatment with 10 mg/kg demonstrated a statistically significant advantage compared with 3 mg/kg in the efficacy outcomes. What is noted in this study was that infliximab treatment with 10 mg/kg was found beneficial in those patients who had not responded to three infusions of infliximab with 3 mg/kg at week 10. It is clinically relevant to escalate the dose of infliximab when patients do not respond to 3 mg/kg.

It was also suggested that higher trough serum infliximab levels by dose escalation of infliximab provided better clinical responses and greater inhibition of progression of joint damage.

**Acknowledgments** This study was funded by Mitsubishi Tanabe Pharma Corporation, Osaka, Japan.

The authors wish to thank all the investigators participated in the RISING study:

F. Hirano, K. Taneichi, T. Atsumi, K. Ohnishi, H. Takahashi, Hokkaido; N. Chiba, Iwate; T. Sasaki, Miyagi; K. Chiba, T. Kanno, Fukushima; S. Ohta, T. Sumida, Ibaraki; T. Yoshio, K. Kurasawa, Tochigi; Y. Handa, T. Mimura, Saitama; R. Matsumura, N. Nakagawa, N. Watanabe, Chiba; K. Saigo, M. Takei, T. Suguro, T. Kasama, M. Hirakata, Y. Kuga, A. Nakajima, K. Yamaji, K. Yamamoto, E. Saito, H. Yamagata, M. Tateishi, S. Sawada, N. Kamatani, H. Yamanaka, M. Nakajima, Tokyo; S. Toma, H. Endo, Kanagawa; T. Kuroda, Niigata; S. Honjo, Toyama; I. Koni, M. Kawano, S. Nakazaki, Ishikawa; K. Sugimoto, Fukui; K. Kanzaki, Yamanashi; T. Kanamono, A. Suzuki, Nagano; T. Ohashi, Y. Kusaka, Gifu; H. Ohashi, Y. Izui, N. Ogawa, T. Miyamoto, Shizuoka; N. Ishiguro, Y. Eto, S. Yoshida, Aichi; S. Tamaki, Mie; T. Fujii, M. Tanaka, Kyoto; M. Inaba, T. Koike, Y. Shimaoka, T. Takeuchi, A. Ogata, Y. Saeki, S. Osawa, K. Shi, Osaka; S. Kumagai, T. Nishiyama, H. Sano, T. Matsubara, Hyogo; Y. Murakawa, Shimane; M. Yamamura, K. Ezawa, Okayama; Y. Yamanishi, S. Yamana, Hiroshima; H. Tanaka, Yamaguchi; K. Tani, Tokushima; M. Tokuda, H. Dobashi, M. Inoo, Kagawa; S. Nakata, K. Takasugi, Ehime; I. Furugou, Y. Tanaka, K. Saito, T. Horiuchi, T. Shuto, Y. Nakashima, H. Miyahara, M. Kondo, Fukuoka; K. Eguchi, Y. Ueki, Nagasaki;

M. Tsukano, Kumamoto; Y. Fujikawa, Oita; T. Matsuda, Kagoshima; Y. Shiohira, Okinawa.

**Conflict of interest statement** All of the authors have received consulting fees from Mitsubishi Tanabe Pharma Corporation, Osaka, Japan.

## References

1. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. *J Rheumatol*. 1998;25:2108–17.
2. Maini RN, Breedveld FC, Kalden JR, Smolen J, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum*. 1998;41:1552–63.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. *N Engl J Med*. 2000;343:1594–602.
4. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum*. 2004;50:3432–43.
5. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. *Arthritis Rheum*. 2006;54:1075–86.
6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum*. 2005;52:3381–90.
7. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *J Rheumatol*. 2006;33:37–44.
8. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum*. 2004;50:1051–65.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*. 1988;31:315–24.
10. Steinbrocker O, Traeger CH, Battersman RC. Therapeutic criteria in rheumatoid arthritis. *JAMA*. 1999;281:615–22.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum*. 1995;38:727–35.
12. Schiff M, Weaver A, Keystone E, Moreland L, Spencer-Green G. Comparison of ACR response, numeric ACR and ACR AUC as measures of clinical improvement in RA clinical trials. *Arthritis Rheum*. 1999;42(Suppl):S81.
13. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med*. 2000;343:1586–93.

14. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995;38:44–8.
15. van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. *Br J Rheumatol.* 1996;35(Suppl 2):4–7.
16. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. *Arthritis Rheum.* 1971;14:706–20.
17. van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in the three-year prospective followup of patients with early rheumatoid arthritis. *Arthritis Rheum.* 1992;35:26–34.
18. Lassere M, Boers M, van der Heijde D, Boonen A, Edmonds J, Saudan A, et al. Smallest detectable difference in radiological progression. *J Rheumatol.* 1999;26:731–9.
19. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum.* 1980;23:137–45.
20. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. *J Rheumatol.* 1993;20:557–60.
21. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. *Ann Rheum Dis.* 2004;63:149–55.
22. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). *Mod Rheumatol.* 2008;18:146–52.
23. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). *Mod Rheumatol.* 2008;18:447–54.
24. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2002;46:1451–9.
25. Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2007;66:1233–8.
26. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF- $\alpha$  biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. *Rheumatology.* 2007;46:1828–34.
27. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. *Ann Rheum Dis.* 2008;67:189–94.



## The Japanese experience with biologic therapies for rheumatoid arthritis

Tsutomu Takeuchi and Hideto Kameda

**Abstract** | The unique genetic, environmental and medical backgrounds of people in Japan might influence the effectiveness and safety of biologic agents in patients with rheumatoid arthritis (RA). Indeed, clinical trials revealed higher response rates to some biologic agents (including infliximab, etanercept and tocilizumab) in patients with RA in Japan than patients treated with the same agents in Western countries, although response rates to adalimumab were comparable in both populations. The reasons why response rates to some biologic agents differ in Japanese individuals is currently under investigation. Post-marketing surveillance data have been collected for all patients with RA who were treated with biologic agents in Japan to monitor drug safety. These data clearly demonstrated that only ~5% of these patients experienced adverse drug reactions to biologic agents, which were well tolerated. Pneumonia, tuberculosis, *Pneumocystis jirovecii* pneumonia and interstitial pneumonitis are considered important severe adverse reactions and risk factors for these adverse effects have been identified. Adverse drug reactions could exaggerate the risks associated with biologic therapy in Japanese patients with RA. Attempts have, therefore, been made to predict clinical response and adverse effects to enable personalized therapy with biologic agents and to optimize the outcomes of these patients.

Takeuchi, T. & Kameda, H. *Nat. Rev. Rheumatol.* 6, 644–652 (2010); published online 28 September 2010; doi:10.1038/nrrheum.2010.154

### Introduction

Given the notable genetic and environmental differences between the populations of Eastern and Western countries, rheumatologists in countries in the Far East, such as Japan, have continually faced challenges concerning the use of biologic agents. Many factors (such as genetic background) can influence the effectiveness and safety of these therapies. For example, within Eastern countries, the frequency of HLA-B27 positivity (which is associated with rheumatic diseases such as ankylosing spondylitis) in the general population of Japan is <1%, whereas in China and Korea the corresponding value is about 5%,<sup>1</sup> which suggests that the Japanese population has a distinct genetic background even compared with other Eastern populations.

Striking differences in environmental factors exist between Japan and Western countries, such as the USA. For example, the incidence of tuberculosis (TB) in Japan in 2002 was 25.8 cases per 100,000 individuals, which was fourfold higher than the corresponding incidence in the USA.<sup>2</sup> This discrepancy raised concerns about the possible increased risk of TB in Japan just as therapies that target tumor necrosis factor (TNF) were introduced to

the Japanese market. This concern is particularly relevant as patients receiving anti-TNF therapy are potentially at an increased risk of TB.<sup>3</sup> Smoking can be associated with an increased risk of developing rheumatoid arthritis (RA). In 2008, the proportion of individuals who smoke in Japan was 39.4% in men and 11.0% in women; smoking rates for men are higher in Japan than they are in the USA, whereas the converse pattern is true in women.<sup>3</sup> In addition, the average body weight of Japanese patients with RA is ~54 kg,<sup>2,4–6</sup> which is only 60–70% that of American patients with RA. This difference, therefore, must be taken into consideration when interpreting the results of clinical trials that used fixed doses of biologic agents, such as etanercept and adalimumab. Finally, treatment profiles and doses of DMARDs and glucocorticoids used in Japan are somewhat different from those used in Western countries (discussed below).<sup>7</sup> The Japanese experience of biologic agents for RA provides a unique view on the biologic agents in use for RA compared to those obtained in Western countries. In addition, the extensive post-marketing surveillance (PMS) for all patients with RA who were treated with biologic agents in Japan is robust and could provide safety information to rheumatologists worldwide.

In this Review, we focus on PMS data and the results of clinical trials of biologic agents for patients with RA in Japan, with particular attention to the distinct genetic, environmental and medical backgrounds of Japanese patients. The effectiveness and safety of biologic agents in Japanese patients with RA are also discussed. Clearly, as outlined in this article, multiple factors

### Competing interests

T. Takeuchi declares associations with the following companies: Abbott, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai Pharmaceuticals, Janssen Pharmaceutica, Mitsubishi Tanabe Pharma, Novartis, Takeda Pharmaceuticals, Wyeth Japan. H. Kameda declares associations with the following companies: Abbott, Centocor Ortho Biotech, Chugai Pharmaceutical, Eisai Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceuticals, Wyeth Japan. See the article online for full details of the relationships.

Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan (T. Takeuchi, H. Kameda).

Correspondence to: T. Takeuchi (tsutake@25.keio.jp)

can alter the efficacy of biologic agents in particular populations. These factors are important to consider in the identification of predictive disease markers or development of personalized treatment regimens.

### DMARD therapy in Japan

Although the focus of this article is on the use of biologic agents in Japanese patients with RA, nonbiologic DMARDs are often administered together with biologic agents, and biologic agents can be indicated for patients with RA who have failed to respond to nonbiologic DMARD therapy. These nonbiologic DMARDs will, therefore, also be briefly discussed here.

### Methotrexate

At present, methotrexate is the drug of choice for RA therapy in Japan, as in many other countries. Methotrexate was approved in 1999 in Japan, but only as a second-line agent for patients with RA who failed to respond to other DMARDs. Moreover, the approved maximum dosage of methotrexate in Japan is 8 mg per week, whereas 15–25 mg per week is the recommended dosage of methotrexate in the USA and many European countries. The approved dosage of methotrexate in Japan was based on a multicenter, randomized, double-blind clinical trial that compared three different once-weekly doses of methotrexate (2 mg, 6 mg and 9 mg) administered for 12 weeks to patients with DMARD-resistant RA. The trial demonstrated that the efficacy of the 6 mg weekly dose was superior to that of the 2 mg weekly dose and comparable to that of 9 mg per week, whereas levels of liver enzymes (aspartate transaminase and/or alanine transaminase) were elevated by 4%, 15%, and 22% (>2.5 times the upper limit of normal) in patients who received the 2 mg per week, 6 mg per week and 9 mg per week doses, respectively. These results suggested that a weekly dose of methotrexate <9 mg was preferable.

Methotrexate at an average dose of 7 mg per week was considered to be effective in approximately half of methotrexate-treated patients with RA,<sup>8</sup> although remission, as determined by the lack of tender or swollen joints and normal serum C-reactive protein levels (0.76–28.5 nmol/l), was only achieved in 11% of patients. Owing to the current requirements for achieving strict treatment targets, such as clinical remission or low scores for disease activity,<sup>9</sup> and the results of a meta-analysis that favored rapid escalation to high doses of methotrexate,<sup>10</sup> the Japan College of Rheumatology has, however, recommended that methotrexate should be approved at a dose of 16 mg per week or higher.

### Bucillamine

10 years ago, bucillamine, a D-penicillamine analogue that was only available in Japan and South Korea, was the most popular DMARD used to treat RA in Japan despite its modest efficacy.<sup>11</sup> The combination of methotrexate and bucillamine is clinically more effective (as confirmed with radiographical findings) than methotrexate monotherapy<sup>12</sup> and this combination therapy is currently used in Japan.

### Key points

- The effectiveness and safety of biologic agents in Japanese patients with rheumatoid arthritis (RA) could be influenced by the unique genetic, environmental and medical backgrounds of these individuals
- Japanese patients with RA with highly active disease and rapid progression of structural joint damage have favorable clinical responses (including retardation of joint destruction) when treated with biologic agents
- Post-marketing surveillance data for all patients with RA treated with biologic agents in Japan demonstrated a low incidence of adverse reactions (~5%)
- In Japanese patients, important adverse reactions to biologic agents include pneumonia, tuberculosis, *Pneumocystis jirovecii* pneumonia and interstitial pneumonitis
- Identification of predictive markers could facilitate personalized therapy with biologic agents and optimize the outcomes of patients with RA

### Leflunomide

Leflunomide was approved for the treatment of patients with RA in Japan in September 2003.<sup>13</sup> However, because of an unexpectedly high prevalence of interstitial lung disease among leflunomide-treated patients in Japan (1.20%, versus an estimated ~0.02% in Western countries)<sup>14</sup> and a high mortality rate (9 of 22 deaths were judged by the study committee members to be caused by leflunomide-induced lung injury),<sup>15</sup> only 6,994 Japanese patients with RA had received leflunomide as of November 2009.<sup>16</sup>

### Tacrolimus


Tacrolimus was approved as a treatment for RA in Japan in April 2005. A positive response to tacrolimus therapy (according to European League Against Rheumatism criteria, that is the Disease Activity Score using 28 joint counts [DAS28]) was achieved in 20% of patients with RA in a single-center cohort study in Japan.<sup>17</sup> This drug has been used, either alone or in combination with methotrexate, in >10,000 Japanese patients with RA.<sup>18</sup>

### Biologic agents used in Japan

Several multicenter, randomized, double-blinded clinical trials of biologic agents have been conducted in Japan and have exhibited excellent rates of remission and ACR 20 responses (a 20% improvement in disease activity according to American College of Rheumatology [ACR] criteria) in patients with RA, as shown in Figures 1 and 2.<sup>4,6,19–23</sup> We believe the clinical trials in Japan are of high quality, that the appropriate patients were selected for inclusion and that clinical assessments by the attending rheumatologists were reproducible; notably, the response rates in placebo groups were low (<10% for monotherapy trials and ~20% for trials in which methotrexate was added to biologic therapy). One of the caveats of the conclusions drawn from these studies is that the dose of biologic agents needed for clinical efficacy is unclear, as detailed below.

### Infliximab

Abe *et al.*<sup>4</sup> evaluated the efficacy of 3 mg/kg and 10 mg/kg doses of infliximab in combination with low-dose methotrexate for the treatment of Japanese patients with



**Figure 1** | Japanese clinical trials of biologic therapies for RA. Clinical trials in Japan of biologic agents (including infliximab, etanercept, adalimumab and abatacept) reported good disease response rates (with or without concomitant methotrexate) in Japanese patients with RA. Most trials assigned roughly equal numbers of patients to receive placebo, low-dose biologic agents or high-dose biologic agents, as follows (placebo versus low dose versus high dose): placebo\* (47 patients) versus infliximab, 3 mg/kg (49 patients); versus 10 mg/kg (51 patients) at weeks 0, 2 and 6 (in combination with a minimum of 6 mg per week methotrexate);<sup>4</sup> placebo (48 patients) versus etanercept, 10 mg twice weekly (50 patients) versus 25 mg twice weekly (49 patients);<sup>20</sup> placebo (53 patients) versus tocilizumab, 4 mg/kg (54 patients) every 4 weeks versus 8 mg/kg every 4 weeks (55 patients);<sup>19</sup> placebo<sup>‡</sup> (66 patients) versus abatacept (in combination with maximum of 8 mg per week methotrexate), 2 mg/kg every 4 weeks (67 patients) versus 10 mg/kg every 4 weeks (61 patients) after 0, 2 weeks induction.<sup>21</sup> Trials of adalimumab compared three different dose regimens: 20 mg twice weekly (87 patients), 40 mg twice weekly (91 patients) and 80 mg twice weekly (87 patients) versus placebo (87 patients).<sup>6</sup> Patients who received infliximab and abatacept had no previous response to methotrexate, whereas patients who received etanercept, tocilizumab and adalimumab were DMARD-resistant. \*Active treatment with methotrexate only. ‡No DMARD treatment. Abbreviations: ACR 20, a 20% improvement in disease activity according to American College of Rheumatology criteria; RA, rheumatoid arthritis.

RA. In this trial, there was no upper limit to the dose of methotrexate, but the average dose of methotrexate was ~7 mg per week for all treatment arms (7.4 mg per week for the placebo group, 7.1 mg per week for the 3 mg/kg infliximab group, and 7.1 mg per week for 10 mg/kg infliximab treatment arm). ACR 20 response rates were similar in the two groups of infliximab-treated patients.<sup>4</sup> This result could have been related to the relatively short period of observation (14 weeks), small sample size ( $n = 147$  patients in total) and the choice of measurement used to evaluate treatment efficacy (the ACR 20 response rate).

A series of investigator-initiated clinical studies, including RECONFIRM (Retrospective Clinical Study on the Notable Efficacy and Related Factors of Infliximab Therapy in a RA Management Group in Japan),<sup>24</sup> and the subsequent follow-up studies RECONFIRM 2<sup>25</sup> and RECONFIRM 2],<sup>26</sup> demonstrated that a 3 mg/kg dose


of infliximab administered at 0, 2, and 6 weeks, and thereafter every 8 weeks, produced excellent clinical responses as well as inhibition of progressive joint destruction in radiographic studies of patients with RA (Figure 2 and Table 1). The inhibition of structural joint damage in RECONFIRM 2]<sup>26</sup> was comparable to that reported in studies conducted in Western countries.<sup>27</sup> A slight decrease in the clinical response to 3 mg/kg of infliximab at around 30–38 weeks was, however, observed.<sup>25</sup> This transient secondary loss in efficacy could be related to insufficient trough levels of infliximab in serum remaining from the previous infusion, presumably because of the 8-week intervals between infusions.

RISING (Impact of Trough Serum Level on Radiographic and Clinical Response to Infliximab Plus Methotrexate in Patients with RA) compared 3 mg/kg, 6 mg/kg and 10 mg/kg doses of infliximab (both in combination with methotrexate).<sup>22</sup> The study used the ACR N index of improvement (or ACR-N, based on the percentage improvement analogous to the ACR 20, ACR 50 and ACR 70 criteria) to define response and included a larger sample of patients ( $n = 327$  patients in total) than the study by Abe and colleagues.<sup>4</sup> The investigators found that 10 mg/kg dose had markedly superior efficacy compared to the 3 mg/kg dose: the DAS28 rate of remission was 45.2% (compared to 30.3% in the low-dose groups), and serum trough levels were increased in patients treated with the high dose of infliximab.<sup>22</sup> Infliximab treatment at both doses was also associated with reduced progression of structural joint damage.<sup>22</sup>

**Etanercept**

The JESMR study (Efficacy and Safety of Etanercept on Active RA Despite Methotrexate Therapy in Japan) compared the efficacy of continuation versus discontinuation of methotrexate at the initiation of etanercept. The findings revealed superior clinical efficacy for continuation of methotrexate therapy (~8 mg per week) at the commencement of etanercept treatment.<sup>23,28</sup> Striking inhibition of structural joint damage was also observed.<sup>28</sup>

As shown in Figure 1, patients treated with the twice-weekly, low dose of 10 mg etanercept had similar ACR 20 response to that of patients treated with the twice-weekly high dose of 25 mg etanercept (ACR 20 response was 64.0% for the low-dose group and 65.3% for the high-dose group),<sup>20</sup> which suggests a ceiling effect with regard to the dose response. A fixed, twice-weekly 25 mg dose of etanercept in Japanese patients with RA<sup>20</sup> (who on average have body weight approximately 70% that of their Western counterparts) might be speculated to exhibit a ceiling effect with regard to achieved blood levels of this agent similar to that observed in patients from Western countries. However, a pharmacokinetic study of etanercept in both Japanese and American individuals (body weight of Japanese healthy volunteers was 63 (±5) kg, while that of American healthy volunteers was 76.1 (±14) kg) showed that serum concentrations and absorption rates of etanercept were similar in both groups of patients, despite receiving the same initial dose of this



**Figure 2** | Effectiveness of biologic agents in Japanese patients with RA. Disease activity was scored according to the DAS28 criteria in Japanese patients with RA after treatment with infliximab, etanercept and tocilizumab (either as a monotherapy or in combination with methotrexate). Remission was defined by the DAS28 criteria plus erythrocyte sedimentation rate <2.6 (except in the RECONFIRM study, in which DAS28 criteria <2.3 plus C-reactive protein levels were used). Abbreviations: DAS, disease activity score; JESMR, Efficacy and Safety of Etanercept on Active RA Despite Methotrexate Therapy in Japan; RA, rheumatoid arthritis; REACTION, Efficacy of Tocilizumab in RA Patients With Daily Clinical Practice in Japan; RECONFIRM, Retrospective Clinical Study on the Notable Efficacy and Related Factors of Infliximab Therapy in a RA Management Group in Japan; RISING, Impact of Trough Serum Level on Radiographic and Clinical Response to Infliximab Plus Methotrexate in Patients with RA; SATORI, Study of Active Controlled Tocilizumab Monotherapy for RA Patients with an Inadequate Response to Methotrexate.

**Table 1** | Japanese studies of structural joint damage after biologic agent therapy for RA

Study characteristics	RECONFIRM 2J <sup>28</sup>	RISING <sup>22</sup>	JESMR <sup>23</sup>	SAMURAI <sup>32</sup>
Biologic therapy	Infliximab	Infliximab	Etanercept	Tocilizumab
Design	Retrospective	Double-blind, controlled	Prospective comparison	Double-blind, controlled
Patients' age per treatment group (years)	50.8	3 mg/kg: 49.9 6 mg/kg: 48.8 10 mg/kg: 50.4	Etanercept: 58.1 Etanercept + methotrexate: 56.5	DMARD: 53.1 Tocilizumab: 52.9
Duration of study per treatment group (year)	7.9	3 mg/kg: 8.3 6 mg/kg: 7.2 10 mg/kg: 8.4	Etanercept: 10.6 Etanercept + methotrexate: 8.1	DMARD: 2.4 Tocilizumab: 2.2
Mean estimated YP at 0 weeks per treatment group (median)	21.3 (16.2)	3 mg/kg: (5.5) 6 mg/kg: (7.6) 10 mg/kg: (6.5)	Etanercept: 17.7 Etanercept + methotrexate: 20.8	DMARD: 12.3 Tocilizumab: 14.1
Mean TSS at 0 weeks per treatment group (median)	104.4 (73.5)	3 mg/kg: (28.0) 6 mg/kg: (32.2) 10 mg/kg: (38.3)	Etanercept: 114.5 Etanercept + methotrexate: 113.1	DMARD: 30.6 Tocilizumab: 28.3
Mean change in TSS over 1 year per treatment group (median)	-0.03 (0)	3 mg/kg: (0) 6 mg/kg: (0.5) 10 mg/kg: (0)	Etanercept: 3.6 Etanercept + methotrexate: 0.8	DMARD: 6.2 (2.5) Tocilizumab: 2.3 (0.5)
Increase in TSS per treatment group (% change from baseline)	0	3 mg/kg: (0) 6 mg/kg: (1.6) 10 mg/kg: (0)	Etanercept: 2.8 Etanercept + methotrexate: 0.7	DMARD: 20.5 Tocilizumab: 8.1


Abbreviations: JESMR, Efficacy And Safety of Etanercept on Active RA Despite Methotrexate Therapy in Japan; RA, rheumatoid arthritis; RECONFIRM 2J, Retrospective Clinical Study on the Notable Efficacy and Related Factors of Infliximab Therapy in a RA Management Group in Japan; 1 Year Outcome of Joint Destruction; RISING, Impact of Trough Serum Level on Radiographic and Clinical Response to Infliximab Plus Methotrexate in Patients with RA; SAMURAI, Study of Active Controlled Monotherapy Used for RA, an IL-6 Inhibitor; TSS, total Sharp score; YP, yearly progression (TSS/disease duration).

agent.<sup>29</sup> This observation argues against body weight as the sole explanation for the existence of the ceiling effect in Japanese patients. An alternative explanation for this ceiling effect might be that patients with mild RA were selected for the study, in part because of the reduced maximum doses of methotrexate in Japan. In patients with milder RA, levels of inflammation and TNF could be lower than in those with severe RA and, therefore, only low doses of TNF inhibitors are needed to neutralize these lower levels of inflammation and TNF.

### Adalimumab

In an adalimumab monotherapy trial,<sup>6</sup> a higher incidence of development of antibodies to adalimumab was observed after 24 weeks of treatment in Japanese patients than was detected in a similar study in Western patients (40.2%, 44.0%, and 26.4% of Japanese patients treated with 20 mg, 40 mg, and 80 mg adalimumab every other week, respectively<sup>6</sup> versus 12% of patients treated with adalimumab in the Western study<sup>10</sup>). This high incidence of antibodies against adalimumab might





**Figure 3** | Collection of post-marketing surveillance data on biologic therapies for RA in Japan. Several strategies have been initiated in Japan to monitor the efficacy and safety of biologic agents in patients with RA. Patients are centrally registered and their baseline demographic data are noted. Clinical disease characteristics and drug safety and efficacy are recorded during and after treatment with biologic agents. These data have been collected since 2003 by pharmaceutical companies, the Japan College of Rheumatology and attending physicians at their respective institutions. Post-marketing surveillance for infliximab (5,000 patients) and etanercept (13,842 patients, 7,091 of whom were included in interim reports) has already been completed. Post-marketing surveillance for tocilizumab and adalimumab is ongoing and expected to be completed by the end of 2010, whereas that for abatacept is yet to be initiated. Abbreviation: RA, rheumatoid arthritis.

have contributed to the low response rates (in patients treated with 20 mg and 40 mg adalimumab every other week, ACR 20 response was 28.7% and 44%, respectively in the Japanese trial,<sup>6</sup> whereas the ACR 20 was 35.8% and 46.0%, respectively in the Western study<sup>30</sup>) to adalimumab therapy in Japanese individuals,<sup>6</sup> and implies that different genetic backgrounds affect the production of antibodies that are specific for biologic agents. In future studies, Japanese patients treated with adalimumab in combination with methotrexate might need to be evaluated for the presence of anti-adalimumab antibodies to see whether this combination therapy could reduce the occurrence of these antibodies and result in similar efficacy to those in Western countries.

**Tocilizumab**

Tocilizumab, a humanized monoclonal antibody against the interleukin (IL)-6 receptor, was first approved in 2008 for the treatment of RA in Japan, and was subsequently approved for use in Europe in 2009 and USA in 2010. Excellent efficacy of tocilizumab monotherapy has been demonstrated in phase II clinical trials with 12 weeks of treatment<sup>19</sup> and with 24 weeks of treatment in the SATORI (Study of Active Controlled Tocilizumab Monotherapy for RA Patients with an Inadequate Response to Methotrexate) trial.<sup>31</sup> In the SAMURAI (Study of Active Controlled Monotherapy Used for RA, an IL-6 Inhibitor) trial, both the total Sharp score and the erosion and joint narrowing scores were markedly lower in the tocilizumab monotherapy group than the conventional DMARD therapy group.<sup>32</sup> This result was the first evidence that biologic agents are superior to DMARDs for inhibiting structural joint damage in Japanese patients with RA (Table 1). No information has

been obtained on the efficacy of combination therapy with tocilizumab and methotrexate in Japanese clinical trials (Figures 1 and 2).

A phase II clinical trial provided the first evidence of the long-term safety and sustainability of using tocilizumab to block IL-6 receptor signaling in patients.<sup>33</sup> The efficacy of tocilizumab was confirmed in the REACTION (Efficacy of Tocilizumab in RA Patients with Daily Clinical Practice in Japan) study, which reported high remission rates (40.7%) at 24 weeks (Figure 2).<sup>34</sup> The findings from REACTION generated interest in whether tocilizumab and methotrexate combination therapy was superior to tocilizumab alone in inhibiting joint damage in Japanese patients with RA, which is currently under investigation in Japan.

**Guidelines**

In Japan, biologic agents are used according to guidelines proposed by the Japan College of Rheumatology.<sup>35,36</sup> These guidelines list the indications for biologic therapy in patients with RA:  $\geq 6$  swollen joints,  $\geq 6$  tender joints and high levels of inflammatory markers (C-reactive protein  $\geq 190.48$  nmol/l) or an erythrocyte sedimentation rate of  $\geq 28$  mm/h) despite  $\geq 3$  months of treatment with one of the DMARDs (including methotrexate, bucillamine and sulfasalazine). These guidelines were further revised to include the administration of etanercept and infliximab to patients with both moderate disease activity and progression of bony erosions.<sup>37</sup> Criteria for the use of tocilizumab<sup>38</sup> and adalimumab<sup>39</sup> have also been devised and used since 2008.

**The safety of biologic agents in Japan PMS programs**

The primary objectives of PMS are to determine the exact frequency of drug-related adverse events (especially opportunistic infections, such as TB) and the factors that affect drug safety and efficacy. PMS data have been collected for all patients with RA who have received biologic agents in Japan since 2003. Pharmaceutical companies, the Japan College of Rheumatology, and attending physicians at their respective institutions have collected data on adverse effects and their treatment (Figure 3). All patients with RA in Japan are centrally registered and baseline demographic information, clinical characteristics and drug safety and efficacy are recorded during the 6 months after starting biologic agents. PMS for infliximab<sup>7</sup> and etanercept<sup>5</sup> in Japan has been completed. Two other PMS programs for tocilizumab and adalimumab in patients with RA were initiated in 2008 and are expected to be completed by the end of 2010 (interim data for tocilizumab is discussed below), at which time PMS data for abatacept will begin to be collected (Figure 2).

The 5,000 patients with RA who received infliximab were 3 years younger on average, consisted of fewer elderly individuals ( $>70$  years of age) and had lower comorbidities than those patients treated with etanercept (interim report for 7,091 patients) (Table 2).<sup>2,5</sup> In addition, all the patients who received infliximab were



also treated with methotrexate in combination, but only 53% of patients were treated with both etanercept and methotrexate (Table 2).

### Adverse drug reactions

Despite the differences in patients' characteristics, treatments, and the time frames of PMS programs, rates of adverse drug reactions (ADR) and severe ADR were comparable for etanercept and infliximab (incidence of ADR 28.0% and 30.6%; incidence of severe ADR 6.2% and 5.7% for infliximab and etanercept, respectively; Table 2).<sup>2,5</sup> The rates of ADR and severe ADR for these two agents were also comparable to those reported in patients treated with tacrolimus (ADR 36.0% and severe ADR 6.4%) in a PMS initiated by a pharmaceutical company that included 3,175 patients treated with tacrolimus for 24 weeks.<sup>18</sup> The similarity of these results indicated that biologic agents are generally well tolerated in Japanese patients with RA.

Rates of adverse events were comparable between tocilizumab-treated and methotrexate-treated groups of patient in short-term trials.<sup>19,31,32</sup> Concerns, however, were raised in relation to the high rates of serious infections in 143 patients exposed to tocilizumab up to 5 years in a phase II clinical trial.<sup>33</sup> 27.5 serious adverse events per 100 patient-years of treatment and 5.7 serious infections per 100 patient-years of treatment occurred.<sup>33</sup> These findings were, however, obtained in a small group of patients (only 66% of the cohort of 143 patients completed 5 years of treatment with tocilizumab)<sup>33</sup> and might be influenced by attrition bias. PMS data for tocilizumab should provide further information with regard to these adverse effects.

Infections such as TB, bacterial pneumonia, *Pneumocystis jirovecii* pneumonia (PCP) and interstitial pneumonitis were the most frequent and important severe ADR in Japanese patients with RA treated with biologic therapy. The risk factors associated with pneumonia or severe infections in PMS for infliximab and etanercept have been identified as advanced age, pulmonary comorbidity, advanced RA (as assessed by disease stage or functional class) and concomitant use of glucocorticoids.<sup>2,5,37</sup>

### Tuberculosis

The overall incidence of TB was 0.3% (14 of 5,000 patients) among patients treated with infliximab enrolled in the PMS program.<sup>2</sup> A substantially higher rate of TB infection was observed in the initial 2,000 patients treated with this agent, which led to concerns about the potential reactivation of latent TB.<sup>40</sup> The initial 2,000 individuals treated with infliximab had not received prophylactic isoniazid despite having risk factors for TB, such as a positive Tuberculin skin test, radiography results that were suspicious for past TB infection, and a history of contact with patients with active TB.<sup>2</sup> Subsequent patients were assessed for risk factors associated with TB and those at risk of the infection received isoniazid prophylaxis, with the result that the rate of TB decreased from 0.55% in the initial 2,000

**Table 2** | Summary of PMS data in Japan for infliximab and etanercept

Parameter	Infliximab (2008) <sup>2</sup>	Etanercept (2009) <sup>5</sup>
<b>Characteristics of treated patients</b>		
Total treated	5,000	7,091
Mean age (years)	55.1	58.3
>70 years old (%)	11.4	19.9
Treated with concomitant methotrexate (%)	100	52.7
Comorbidity (%)	38.4	58.2
<b>Adverse drug reactions*</b>		
Total (%)	28.0	30.6
Severe adverse drug reactions (%)	6.2	5.7
Pneumonia (%)	2.2	1.4
<i>Pneumocystis jirovecii</i> pneumonia (%)	0.4	0.2
Tuberculosis (%)	0.3	0.1
Interstitial pneumonitis (%)	0.5	0.6
Severe infusion reaction (%)	0.5	0

\*Only the five most clinically important adverse reactions are individually mentioned. Abbreviation: PMS, post-marketing surveillance data.

patients to 0.1% in the subsequent 3,000 individuals. As PMS information on infliximab was extensively shared among rheumatologists in Japan, the incidence of TB in patients treated with etanercept was comparable to that in the final 3,000 infliximab-treated patients (0.1%),<sup>5</sup> owing to the implementation of measures to reduce the risk of this infection

### *Pneumocystis jirovecii* pneumonia

PCP is an important opportunistic infection in patients with AIDS, but the exact incidence of this form of pneumonia in patients with RA who are treated with TNF inhibitors was not well characterized until publication of the Japanese PMS data for infliximab.

The Japan College of Rheumatology PMS committee reported that the incidence of PCP was 0.4% in the 5,000 patients enrolled in the PMS program for infliximab,<sup>2</sup> which is more than 10 times higher than the reported incidence of this infection in data from Western studies of this agent.<sup>41</sup> The median time to develop PCP was 8.5 weeks from the first infusion of infliximab; this complication tended to develop in elderly patients, those with pulmonary comorbidities such as interstitial lung diseases, and those who received high doses of glucocorticoids.<sup>42</sup> In addition, decreased serum albumin and IgG levels were also identified in infliximab-treated patients with RA at the onset of PCP; however, these risk factors are not specific to this infection and can be observed in other opportunistic and common infections.

Interestingly, *P. jirovecii* infection in patients with RA who were receiving immunosuppressive treatment seemed to have different clinical features and radiographic findings (in high-resolution chest CT scans) from those of patients with HIV infections.<sup>43</sup> Patients with RA who were treated with biologic agents tended to deteriorate rapidly (within weeks), while

patients with HIV infection progressed more slowly (within weeks to months). The disparity between these two groups of patients suggests that a unique mechanism might underlie the pathogenesis of PCP in patients with RA, possibly resulting from macrophage activation by C-type lectin domain family 7 member A (also termed dectin 1) or lactosylceramide.<sup>44–46</sup>

80% of infliximab-treated patients with RA who had PCP developed acute respiratory failure, although all survived with appropriate treatment. During the PMS for etanercept, PCP developed in 0.2% of patients enrolled in PMS programs for etanercept in Japan. Six of these 25 patients died.<sup>5</sup> This result raised a particular concern that Japanese patients treated with TNF-blocking agents might have increased risk of PCP and highlighted the need for antibiotic prophylaxis with co-trimoxazole (sulfamethoxazole combined with trimethoprim) in patients at risk of this infection. In this regard, measuring serum levels of  $\beta$ -D-glucans might be useful for the diagnosis and monitoring of the development of PCP in patients with RA.<sup>47</sup>

#### *Interstitial lung disease*

Interstitial lung disease was observed in 0.5% and 0.6% of individuals treated with infliximab and etanercept, respectively<sup>2,5</sup>, which is consistent with the incidence of this complication in DMARD-treated patients (0.38–1.53 per 100 patient-year).<sup>48,49</sup> Findings from PMS data, however, show that 75% of patients who developed interstitial lung disease during etanercept treatment were not concomitantly treated with methotrexate, which implies that interstitial lung disease in etanercept-treated patients cannot be considered a confounding effect of concomitant methotrexate treatment. The incidence of interstitial lung disease was considerably increased in leflunomide-treated patients (1.2% in PMS data).<sup>14</sup>

Findings from studies of dermatomyositis and gefitinib-induced or leflunomide-induced lung injury suggest that Japanese patients might be particularly predisposed to develop interstitial lung disease, or at least have increased susceptibility to its exacerbation.<sup>50–52</sup> In addition to the influence of genetic background, environmental factors (such as the presence of airway colonization with *P. jirovecii*) could underlie the apparently elevated incidence of both PCP and interstitial lung disease in Japanese patients with RA. Patients with pre-existing lung disease, such as subclinical pulmonary inflammation elicited by either colonization with pathogens or by RA itself (owing to the immunomodulatory effects of biologic and DMARD therapy) might, therefore, subsequently develop clinical pulmonary complications.

#### **Discontinuation of biologic agents**

Clinical studies have evaluated whether biologic agents can be discontinued in patients with RA who maintain a low disease activity owing to the sustained benefit of these drugs after treatment withdrawal. A clinical study to examine the pharmacokinetics of infliximab was carried out in Japan with a small number of established

DMARD-resistant patients with RA.<sup>53</sup> These patients received 3 mg/kg infliximab at 0, 2, and 6 weeks without concomitant methotrexate. After completion of the trial, the patients did not receive further biologic agents, but were treated with DMARDs, including methotrexate. Surprisingly, nearly half of the patients had persistently stable levels of disease activity 1 year after the trial ended, which demonstrated that infliximab could be discontinued in selected patients with RA.<sup>53</sup> Given the evidence that suggested patients with early RA can discontinue infliximab if they achieve stable remission or low disease activity scores,<sup>54,55</sup> a clinical study of infliximab discontinuation in patients with established RA was initiated. Of the 102 patients who could be evaluated, around half successfully discontinued infliximab during the 1-year follow-up. 67% of the patients who were able to discontinue infliximab had no radiographic evidence of disease progression.<sup>56</sup> A treatment strategy that uses tightly controlled doses of biologic agents to induce clinical remission or low disease activity, followed by discontinuation of the biologic agents once a low disease activity has been achieved, could be advantageous from both the patient's health status and economic points of view. This 'response-driven' treatment strategy is now being examined in several clinical studies and trials in Japan for several biologic agents, including infliximab, etanercept, tocilizumab and abatacept.

#### **Predicting response to biologic agents**

Medical treatment can be personalized for individual patients with RA by predicting the efficacy and safety of a given biologic agent. An enormous effort is underway to identify factors that can accurately predict responses to treatment. Several clinical variables have been associated with efficacy and safety, but these markers are often unrealistic markers to use in clinical practice. For example, the finding that the response rate to a certain biologic agent is increased in young patients with RA (<45 years of age)<sup>57</sup> is not applicable to the treatment of elderly individuals (>65 years of age). Clinical studies using modern technology and analyses of molecular data (including genetic polymorphisms<sup>58,59</sup> and comprehensive messenger RNA expression analysis)<sup>60,61</sup> have identified numerous candidate molecules for predicting the efficacy of biologic agents: tristetraprolin,<sup>62</sup> the products of interferon-related genes,<sup>60</sup> phosphoserine phosphatase<sup>61</sup> and disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5).<sup>63</sup> At present, however, consensus has not been reached as to which molecules offer truly accurate and generalizable predictions of the efficacy of biologic therapies for RA.<sup>64,65</sup> Many investigators are also extensively searching for factors that can predict ADR (including infections<sup>66</sup> and infusion reactions) associated with biologic agents by examining genetic polymorphisms in patients with RA.

#### **Conclusions**

Experience with biologic therapies in Japanese patients with RA has shown that these agents have good efficacy. However, several important adverse effects, such as

opportunistic infections, have an elevated incidence in Japanese patients, which could amplify the risks associated with biologic therapies for RA in Japan. Attention should be closely focused on the differences between patients with RA from different ethnic backgrounds. Treatment of RA should ultimately be individualized to each patient's needs to maximize drug efficacy and minimize the associated risks. Future research could identify factors that can predict the response to treatment with biologic agents and the risks of adverse effects associated with these drugs to improve patients' outcomes further.

#### Review criteria


We searched for original and review articles focusing on rheumatoid arthritis, biologic agents and Japan in MEDLINE and PubMed published between 2003 and 2010 in the English language. The search terms we used were "arthritis", "rheumatoid", "infliximab", "TNFR-Fc fusion protein", "adalimumab", "tocilizumab", "abatacept" and "Japan". We also searched the reference lists of identified articles for further papers and also included articles on websites, some of which are in Japanese.

- Khan, M. A. HLA-B27 and its subtypes in world populations. *Curr. Opin. Rheumatol.* 7, 263–269 (1995).
- Takeuchi, T. et al. Postmarketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. *Ann. Rheum. Dis.* 67, 189–194 (2008).
- Health white paper [Japanese]. *Japanese Ministry of Health* [online], <http://www.mhlw.go.jp/wp/hakusyo/kousei/09-02/kousei-data/pdf/Index.html> (2010).
- Abe, T. et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *J. Rheumatol.* 33, 37–44 (2006).
- Koike, T. et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. *J. Rheumatol.* 36, 898–906 (2009).
- Miyasaka, N.; CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. *Mod. Rheumatol.* 18, 252–262 (2008).
- Sokka, T., Ervalds, M. & Pincus, T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. *Mod. Rheumatol.* 18, 228–239 (2008).
- Kameda, H. et al. Factors predicting response to a low-dose methotrexate therapy in patients with rheumatoid arthritis: A better response in male patients. *Mod. Rheumatol.* 14, 442–446 (2004).
- Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann. Rheum. Dis.* 69, 631–637 (2010).
- Visser, K. & van der Heijde, D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann. Rheum. Dis.* 68, 1094–1099 (2009).
- Sekiguchi, N., Kameda, H., Arano, K. & Takeuchi, T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. *Mod. Rheumatol.* 16, 85–91 (2006).
- Ichikawa, Y. et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. *Mod. Rheumatol.* 15, 323–328 (2005).
- Osiri, M. et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. *J. Rheumatol.* 30, 1182–1190 (2003).
- Sawada, T. et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. *Rheumatology (Oxford)* 48, 1069–1072 (2009).
- Sato, T. et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. *Rheumatology (Oxford)* 48, 1265–1268 (2009).
- Safety information of leflunomide in Japan [Japanese]. *Sanofi-Aventis* [online], <http://safety.sanofi-aventis.co.jp/areva/aravap/index.html> (2010).
- Suzuki, K. et al. Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. *Rheumatol. Int.* 29, 431–436 (2009).
- Takeuchi, T., Kawai, S., Yamamoto, K. & Miyasaka, N. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. *Ann. Rheum. Dis.* 69 (Suppl. 3), 219 (2010).
- Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum.* 50, 1761–1769 (2004).
- Phase II dose-finding clinical trials for abatacept [Japanese]. *Enbrel* [online], <http://www.enbrel.jp/member/data/result.html> (2010).
- Takeuchi, T., Abe, T., Yamamoto, A. & Miyasaka, N. New biologics for rheumatoid arthritis in Japan: A multi-center randomized double-blind, controlled, dose-response study of abatacept (BMS-188667) in Japanese active rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. *Mod. Rheumatol.* 19, S32 (2009).
- Takeuchi, T., Miyasaka, N., Inoue, K., Abe, T. & Koike, T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. *Mod. Rheumatol.* 19, 478–487 (2009).
- Kameda, H. et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: A randomized trial. *Mod. Rheum.* doi:10.1007/s10165-010-0324-4.
- Yamanaka, H. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). *Mod. Rheumatol.* 17, 28–32 (2007).
- Tanaka, Y. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical and radiographic outcomes (RECONFIRM-II). *Mod. Rheumatol.* 18, 146–152 (2008).
- Takeuchi, T. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). *Mod. Rheumatol.* 18, 447–454 (2008).
- Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. *Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.* 343, 1594–1602 (2000).
- Kameda, H. et al. Etanercept (ETN) plus methotrexate (MTX) combination therapy resulted in a better outcome in joint damage and physical function than ETN monotherapy even in patients with active rheumatoid arthritis despite MTX treatment: 52-week results from the JESMR study. *Ann. Rheum. Dis.* 68 (Suppl. 3), 121 (2009).
- Kawai, S. et al. Comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. *J. Clin. Pharmacol.* 46, 418–423 (2006).
- van de Putte, L. B. et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann. Rheum. Dis.* 63, 508–516 (2004).
- Nishimoto, N. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Mod. Rheumatol.* 19, 12–19 (2009).
- Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann. Rheum. Dis.* 66, 1162–1167 (2007).
- Nishimoto, N. et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. *Ann. Rheum. Dis.* 68, 1580–1584 (2009).
- Yamanaka, H. et al. Efficacy of tocilizumab in rheumatoid arthritis patients with daily clinical practice in Japan: Results from a retrospective study (REACTION). *Ann. Rheum. Dis.* 69 (Suppl. 3), 547 (2010).
- Miyasaka, N., Takeuchi, T. & Eguchi, K. Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. *Mod. Rheumatol.* 15, 4–8 (2005).
- Miyasaka, N., Takeuchi, T. & Eguchi, K. Guidelines for the proper use of etanercept in Japan. *Mod. Rheumatol.* 16, 63–67 (2006).
- Koike, R., Takeuchi, T., Eguchi, K. & Miyasaka, N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. *Mod. Rheumatol.* 17, 451–458 (2007).
- Koike, R. et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. *Mod. Rheumatol.* 19, 351–357 (2009).

39. Guidelines for adalimumab [Japanese]. *Japan College of Rheumatology* [online], [http://www.ryumachi-jp.com/info/080724\\_ADA.html](http://www.ryumachi-jp.com/info/080724_ADA.html) (2008).
40. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N. Engl. J. Med.* **345**, 1098–1104 (2001).
41. Arthritis advisory committee. Safety Update on TNF- $\alpha$  antagonists: infliximab and etanercept. FDA [online], [http://www.fda.gov/OHRMS/DOCKETS/ac/01/briefing/3779b2\\_01\\_1-CBER\\_briefing\\_safety.pdf](http://www.fda.gov/OHRMS/DOCKETS/ac/01/briefing/3779b2_01_1-CBER_briefing_safety.pdf) (2001).
42. Komano, Y. et al. *Pneumocystis jirovecii* pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. *Arthritis Rheum.* **61**, 305–312 (2009).
43. Tokuda, H. et al. Clinical and radiological features of *Pneumocystis pneumonia* in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and *Pneumocystis pneumonia* in acquired immunodeficiency syndrome: a multicenter study. *Intern. Med.* **47**, 915–923 (2008).
44. Saijo, S. et al. Dectin-1 is required for host defense against *Pneumocystis carinii* but not against *Candida albicans*. *Nat. Immunol.* **8**, 39–46 (2007).
45. Steele, C. et al. Alveolar macrophage-mediated killing of *Pneumocystis carinii* f. sp. *muris* involves molecular recognition by the Dectin-1  $\beta$ -glucan receptor. *J. Exp. Med.* **198**, 1677–1688 (2003).
46. Hahn, P. Y. et al. *Pneumocystis carinii* cell wall  $\beta$ -glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. *J. Biol. Chem.* **278**, 2043–2050 (2003).
47. Tasaka, S. et al. Serum indicators for the diagnosis of pneumocystis pneumonia. *Chest* **131**, 1173–1180 (2007).
48. Ohosone, Y. et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. *J. Rheumatol.* **24**, 2299–2303 (1997).
49. Shidara, K. et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. *Mod. Rheumatol.* **20**, 280–286 (2010).
50. Kameda, H. & Takeuchi, T. Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. *Endocr. Metab. Immune Disord. Drug Targets* **6**, 409–415 (2006).
51. Azuma, A., Hagiwara, K. & Kudoh, S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. *Am. J. Respir. Crit. Care Med.* **177**, 1397–1398 (2008).
52. Kudoh, S. et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. *Am. J. Respir. Crit. Care Med.* **177**, 1348–1357 (2008).
53. Abe, T. & Takeuchi, T. The other side of TNF-targeted therapy of patients with rheumatoid arthritis. *Curr. Rheumatol. Rep.* **3**, 1–2 (2001).
54. Quinn, M. A. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* **52**, 27–35 (2005).
55. van der Kooij, S. M. et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. *Ann. Rheum. Dis.* **68**, 914–921 (2009).
56. Tanaka, Y. et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. *Ann. Rheum. Dis.* **69**, 1286–1291 (2010).
57. Radovits, B. J. et al. Influence of age on the outcome of antitumor necrosis factor alpha therapy in rheumatoid arthritis. *Ann. Rheum. Dis.* **68**, 1470–1473 (2009).
58. Tutuncu, Z. et al. Fc $\gamma$  receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. *Arthritis Rheum.* **52**, 2693–2696 (2005).
59. Canete, J. D. et al. Influence of variants of Fc $\gamma$  receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor  $\alpha$  therapy in rheumatoid arthritis. *Ann. Rheum. Dis.* **68**, 1547–1552 (2009).
60. Sekiguchi, N. et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF- $\alpha$  monoclonal antibody, infliximab. *Rheumatology (Oxford)* **47**, 780–788 (2008).
61. Tanino, M. et al. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. *Biochem. Biophys. Res. Commun.* **387**, 261–265 (2009).
62. Sugihara, M. et al. Effects of infliximab therapy on gene expression levels of tumor necrosis factor  $\alpha$ , tristetraprolin, T cell intracellular antigen 1, and Hu antigen R, in patients with rheumatoid arthritis. *Arthritis Rheum.* **56**, 2160–2169 (2007).
63. Tsuzaka, K., Itami, Y., Takeuchi, T., Shinozaki, N. & Morishita, T. ADAMTS5 is a biomarker for prediction of the response to infliximab in patients with rheumatoid arthritis. *J. Rheumatol.* **37**, 1454–1460 (2010).
64. Kastbom, A. et al. Fc $\gamma$  receptor type IIIA genotype and response to tumor necrosis factor  $\alpha$ -blocking agents in patients with rheumatoid arthritis. *Arthritis Rheum.* **56**, 448–452 (2007).
65. Pavy, S. et al. Tumor necrosis factor  $\alpha$ -308G>A polymorphism is not associated with response to TNF $\alpha$  blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. *Ann. Rheum. Dis.* **69**, 1022–1028 (2010).
66. Hughes, L. B. et al. Genetic risk factors for infection in patients with early rheumatoid arthritis. *Genes Immun.* **5**, 641–647 (2004).

**Author contributions**

Both authors contributed equally to all aspects of this manuscript.



To order reprints, please contact:

Americas: Tel 212 726 9278; Fax 212 679 0843; [author-reprints@nature.com](mailto:author-reprints@nature.com)  
 Europe/UK/ROW: Tel +44 (0)20 7833 4000; Fax +44 (0)20 7843 4500; [author-reprints@nature.com](mailto:author-reprints@nature.com)  
 Japan & Korea: Tel +81 3 3267 8751; Fax +81 3 3267 8746; [reprints@naturejpn.com](mailto:reprints@naturejpn.com)



## A regulatory variant in *CCR6* is associated with rheumatoid arthritis susceptibility

Yuta Kochi<sup>1,12</sup>, Yukinori Okada<sup>2,3,12</sup>, Akari Suzuki<sup>1</sup>, Katsunori Ikari<sup>4</sup>, Chikashi Terao<sup>5</sup>, Atsushi Takahashi<sup>2</sup>, Keiko Yamazaki<sup>6</sup>, Naoya Hosono<sup>6</sup>, Keiko Myouzen<sup>1</sup>, Tatsuhiko Tsunoda<sup>7</sup>, Naoyuki Kamatani<sup>2</sup>, Tatsuya Furuichi<sup>8</sup>, Shiro Ikegawa<sup>8</sup>, Koichiro Ohmura<sup>5</sup>, Tsuneyo Mimori<sup>5</sup>, Fumihiko Matsuda<sup>9</sup>, Takuji Iwamoto<sup>4</sup>, Shigeki Momohara<sup>4</sup>, Hisashi Yamanaka<sup>4</sup>, Ryo Yamada<sup>1,9</sup>, Michiaki Kubo<sup>6</sup>, Yusuke Nakamura<sup>10,11</sup> & Kazuhiko Yamamoto<sup>1,3</sup>

Rheumatoid arthritis is a common autoimmune disease with a complex genetic etiology. Here, through a genome-wide association study of rheumatoid arthritis, we identified a polymorphism in *CCR6*, the gene encoding chemokine (C-C motif) receptor 6 (a surface marker for Th17 cells) at 6q27, that was associated with rheumatoid arthritis susceptibility and was validated in two independent replication cohorts from Japan (rs3093024, a total of 7,069 individuals with rheumatoid arthritis (cases) and 20,727 controls, overall odds ratio = 1.19,  $P = 7.7 \times 10^{-19}$ ). We identified a triallelic dinucleotide polymorphism of *CCR6* (*CCR6DNP*) in strong linkage disequilibrium with rs3093024 that showed effects on gene transcription. The *CCR6DNP* genotype was correlated with the expression level of *CCR6* and was associated with the presence of interleukin-17 (IL-17) in the sera of subjects with rheumatoid arthritis. Moreover, *CCR6DNP* was associated with susceptibility to Graves' and Crohn's diseases. These results suggest that *CCR6* is critically involved in IL-17-driven autoimmunity in human diseases.

Rheumatoid arthritis manifests as inflammation of synovial tissue and joint destruction. The T-cell-driven autoimmune response and the inflammatory cytokine cascade are two important arms of rheumatoid arthritis pathogenesis, involving both environmental and genetic factors<sup>1</sup>. The etiological role of CD4<sup>+</sup> helper T cells is supported by evidence that the specific alleles of the *HLA-DRB1* gene encoding the major histocompatibility complex class II proteins are associated with disease risk<sup>2</sup>. Among the subsets of helper T cells, Th1 cells that characteristically produce interferon- $\gamma$  are considered to have a prominent role in rheumatoid arthritis, as they are highly prevalent in the synovial tissues of subjects with the disease<sup>3,4</sup>. Moreover, a

newly identified subset of helper T cells that produces IL-17, hence termed Th17 cells<sup>5</sup>, are now thought to have an important role in rheumatoid arthritis, as has been demonstrated in several mouse arthritis models<sup>6-8</sup>. However, less is known about the role of Th17 cells in human rheumatoid arthritis. In fact, among the loci identified in recent genome-wide association studies (GWAS) of rheumatoid arthritis, few have been identified that may affect the axis of Th17 cells specifically, with the exception of the genetic markers near *IL21*<sup>9-12</sup>.


To identify rheumatoid arthritis susceptibility loci in the Japanese population, we performed a GWAS by genotyping over 550,000 SNP markers. We applied stringent quality-control criteria and tested 2,303 rheumatoid arthritis cases (of whom 79.2% were positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies; **Supplementary Table 1**) and 3,380 controls for 393,217 autosomal SNPs with minor allele frequency of >0.05. The results of principal-component analysis (PCA)<sup>13</sup> did not demonstrate substantial population stratification in our study population (**Supplementary Fig. 1** and **Supplementary Note**), as has not been previously anticipated for the Japanese population<sup>14</sup>. The inflation of test statistics,  $\lambda_{\text{genomic control}} (\lambda_{\text{GC}})$ <sup>15</sup>, was 1.097. We identified significant associations in two chromosomal regions (6p21 and 6q27) that satisfied a genome-wide significance threshold of  $P < 5 \times 10^{-8}$  (**Fig. 1a** and **Supplementary Fig. 2**). The peak of association in 6p21 was observed at a SNP near *HLA-DRB1* at the major rheumatoid arthritis susceptibility locus (rs13192471,  $P = 1.9 \times 10^{-58}$ , OR = 1.97, 95% CI 1.82–2.14; **Supplementary Table 2**). Among the markers in 6q27, the smallest  $P$  value was observed at a SNP in the region containing *CCR6* (rs3093024,  $P = 4.5 \times 10^{-10}$ , OR = 1.27, 95% CI 1.18–1.37; **Fig. 1b**, **Table 1** and **Supplementary Tables 2** and **3**). The association of rs3093024 was still significant after PCA correction<sup>13</sup> ( $P = 5.5 \times 10^{-9}$ ). We observed suggestive associations ( $5 \times 10^{-8} \leq P < 1 \times 10^{-5}$ ) in five

<sup>1</sup>Laboratory for Autoimmune Diseases, Center for Genomic Medicine (CGM), RIKEN, Yokohama, Japan. <sup>2</sup>Laboratory for Statistical Analysis, CGM, RIKEN, Yokohama, Japan. <sup>3</sup>Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. <sup>4</sup>Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan. <sup>5</sup>Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan. <sup>6</sup>Laboratory for Genotyping Development, CGM, RIKEN, Yokohama, Japan. <sup>7</sup>Laboratory for Medical Informatics, CGM, RIKEN, Yokohama, Japan. <sup>8</sup>Laboratory for Bone and Joint Diseases, CGM, RIKEN, Yokohama, Japan. <sup>9</sup>Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. <sup>10</sup>Laboratory for International Alliance, CGM, RIKEN, Yokohama, Japan. <sup>11</sup>Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. <sup>12</sup>These authors contributed equally to this work. Correspondence should be addressed to Y.K. (ykoichi@src.riken.jp).

Received 19 January; accepted 6 April; published online 9 May 2010; doi:10.1038/ng.583



**Figure 1** Results of GWAS and expression analysis around *CCR6*. (a) A Manhattan plot showing the  $-\log_{10}(P)$  value of SNPs in the GWAS for 2,303 Japanese rheumatoid arthritis cases and 3,380 controls. Some SNPs in the HLA region are not included because they exceeded the upper limit of the plot. (b) LD map (upper), genomic structure (middle) and  $-\log_{10}(P)$  value of SNPs in the GWAS (lower) around *CCR6*. The  $D'$ -based LD map (upper) is drawn based on the genotype data of rheumatoid arthritis cases and controls enrolled in the GWAS using Haploview software version 4.1. LD blocks involved in the selection of tag SNPs and the expression analysis are highlighted with a yellow bar. The diamond dots (lower) represent respective SNPs. Their densities in red represent LD indices ( $R^2$ ), with rs3093024 indicated as the largest dot. (c) Correlation between the genotypes of rs3093024 and the transcript levels of *CCR6*-a (NM\_031409) in EBV-transfected cell lines ( $n = 57$ ) stimulated with PMA. (d) The coefficients of determination,  $r^2$ , of SNPs in the correlation analysis between the genotypes and the expression levels of *CCR6*-a transcripts. The correlation peak was observed at rs3093024. The red or gray dotted lines represent the correspondence of the chromosomal positions in b and d (the red line represents rs3093024). The plots of b and d were drawn by using SNAP version 2.1.



chromosomal regions, which included the region containing the previously associated *STAT4* locus<sup>16–18</sup> (Supplementary Table 2). The association results for other previously reported loci<sup>9–12,16,19</sup> are summarized in Supplementary Table 4, including replications for the *PADI4* and *TNFAIP3* loci (both  $P < 0.01$ ).

To validate the association with *CCR6*, we performed a replication study using two independent Japanese rheumatoid arthritis case-control cohorts (cohort 1 consisted of 3,662 cases and 15,873 controls, and cohort 2 consisted of 1,106 cases and 1,486 controls). The association of rs3093024 was replicated in both sets ( $P = 6.3 \times 10^{-9}$  and  $P = 3.1 \times 10^{-3}$  in the two individual cohorts, respectively; combined-analysis  $P = 7.7 \times 10^{-19}$ , OR = 1.19, 95% CI 1.15–1.24; Table 1). A concurrent study<sup>20</sup> also identified an association at the *CCR6* region with rheumatoid arthritis in European populations by performing


a meta-analysis of GWAS from a collection of 5,539 autoantibody-positive rheumatoid arthritis cases and 20,169 controls, in which the strongest signal was observed at a SNP in *CCR6* (rs3093023,  $P = 3.3 \times 10^{-7}$ , OR = 1.13). The landmark SNP in the Japanese population

**Table 1** Association analysis of rs3093024 in *CCR6* with rheumatoid arthritis

Population	Study set	Number of subjects		Allele T frequency		OR (95%CI)	P value
		Cases	Controls	Cases	Controls		
Japanese	GWAS	2,301	3,368	0.52	0.46	1.27 (1.18–1.37)	$4.9 \times 10^{-10}$
	Replication study 1 <sup>a</sup>	3,662	15,873	0.50	0.46	1.16 (1.11–1.22)	$6.3 \times 10^{-9}$
	Replication study 2 <sup>a</sup>	1,106	1,486	0.51	0.47	1.18 (1.06–1.32)	0.0031
	Combined analysis <sup>b</sup>	7,069	20,727	0.51	0.46	1.19 (1.15–1.24)	$7.7 \times 10^{-19}$
European	GWAS meta-analysis <sup>c</sup>	5,539	20,169	0.47	0.43	1.13 (1.08–1.18)	$3.6 \times 10^{-7}$

<sup>a</sup>Cochran-Armitage trend test. <sup>b</sup>Meta-analysis of GWAS and replication studies 1 and 2 (Mantel-Haenszel method). <sup>c</sup>Additive model logistic regression (Wald test) in six GWAS collections and meta-analysis across collections by inverse variance-weighted z-scores. Details of the European GWAS meta-analysis are described elsewhere<sup>20</sup>. GWAS, genome-wide association study; OR, odds ratio.

**Figure 2** CCR6DNP genotype is correlated with the expression level of *CCR6* and IL-17 status of rheumatoid arthritis cases. (a) Genomic position of disease-associated polymorphisms in *CCR6* (CCR6-a and CCR6-b correspond to transcripts NM\_031409 and NM\_004367 in GenBank, respectively). (b) A newly identified SNP in the 3' flanking sequence of rs968334. (c) Binding of nuclear factors from PSC cells to the 31-bp sequences around each allele of CCR6DNP was evaluated by EMSA. Unlabeled probes in 400-fold excess as compared to the labeled probes were used for the competition experiment. The densities of bands were quantified and normalized to that of the TG allele, and significant allelic differences were observed (the mean intensities from four independent experiments were 0.26, 0.76 and 1 for CA, CG and TG, respectively;  $P < 0.0001$  by Student's *t*-test). (d) Enhanced activity of the 31-bp sequence region around CCR6DNP as evaluated by luciferase assay. SV40, promoter sequence of SV40; luc, luciferase. Data represent mean  $\pm$  s.e.m. Representative data from three experiments performed in octuplicate are shown. \* $P = 1.3 \times 10^{-7}$ , \*\* $P = 7.4 \times 10^{-5}$  and \*\*\* $P = 0.0024$  by Student's *t*-test. (e) Correlation between CCR6DNP genotype and expression of *CCR6* as measured by quantitative TaqMan PCR of PSC cells ( $n = 57$ ). (f) Correlation between CCR6DNP genotype and IL-17 status in the sera of rheumatoid arthritis cases. The ratios of cases that showed detectable levels of IL-17 ( $>4$  pg/ml) are shown above (IL-17 active cases) and are significantly associated with the CCR6DNP genotype ( $P = 1.2 \times 10^{-3}$  by trend test).



(rs3093024) was in almost absolute linkage disequilibrium (LD) with rs3093023 in the European population ( $r^2 > 0.99$  and  $D' > 0.99$ ) and showed a similar level of association ( $P = 3.6 \times 10^{-7}$ , OR = 1.13). Together, these results provide strong evidence for association of the *CCR6* locus with risk of rheumatoid arthritis. This locus encompasses several genes, three of them in the region showing strong LD with rs3093024 (Fig. 1b) and six located within 0.5 Mb of either side of this LD region. Although the disease-associated polymorphisms may affect the function of these flanking genes, there is no bibliographical evidence so far showing their functional relevance in rheumatoid arthritis pathogenesis other than that previously shown for *CCR6*.

Recent studies have shown that *CCR6* is a specific marker for Th17 cells, distinguishing them from other helper T-cells<sup>8,21</sup>, although *CCR6* is also expressed in IL-17-producing  $\gamma\delta$  T cells<sup>22</sup> as well as in subsets of B cells and dendritic cells<sup>23</sup>. Considering the roles of these cells in the pathogenesis of rheumatoid arthritis, *CCR6* is a strong candidate gene in the locus. In a search for causal variants, we first sequenced the *CCR6* coding region in 24 rheumatoid arthritis cases but found no variation that alters its amino acid sequence. We then evaluated whether the *CCR6* polymorphisms could affect gene expression. Epstein-Barr virus (EBV)-transfected cell lines established from Japanese individuals (Pharma SNP Consortium (PSC) cells,  $n = 57$ ) were examined for the expression levels of two major *CCR6* transcripts (NM\_031409 and NM\_004367 in GenBank, termed here CCR6-a and CCR6-b, respectively). Correlation analysis between the SNP genotype and gene expression level showed a significant correlation between rs3093024 and CCR6-a, not present in resting cells but rather seen in cells stimulated with phorbol myristate acetate (PMA) ( $R^2 = 0.21$ ,  $P = 3.2 \times 10^{-4}$  Fig. 1c). The expression levels increased with the number of risk (T) alleles. A similar trend was observed for CCR6-b, but this trend was not statistically significant at a level of  $\alpha = 0.05$ . These observations suggested the presence of regulatory variants in this region that could affect expression levels, especially those of CCR6-a.

To search for regulatory variants, we expanded the region for analysis to approximately 210 kb, covering the entire *CCR6* gene and the surrounding LD blocks containing disease-associated SNPs with  $P < 10^{-3}$  (Fig. 1b). In addition to the SNPs registered in the Phase II HapMap database for Japanese samples<sup>24</sup>, we identified 19 newly discovered SNPs by resequencing the 12-kb region that comprises the 5' flanking region of *CCR6* in 24 rheumatoid arthritis cases (Supplementary Fig. 3a). Of these 312 SNPs, 40 tag SNPs were selected for further correlation analysis with gene expression using a threshold of  $r^2 > 0.8$ . Correlation analysis revealed a peak of correlation at rs3093024 with the expression level of CCR6-a in cells stimulated with PMA (Fig. 1d).

This concordance of peaks in rs3093024 that correlated disease susceptibility with *CCR6* expression made this SNP, or variants in LD with it, a strong candidate as a causal variant. We thus examined all identified SNPs in strong LD ( $r^2 > 0.8$ ) with rs3093024 for their potential to affect gene expression (Supplementary Fig. 3a). Allelic differences in binding of nuclear proteins were first evaluated for the sequences surrounding each SNP by electrophoretic mobility shift assays (EMSA) using nuclear extracts from PSC cells. Of the six SNPs examined, only rs968334 (located 6.7 kb upstream of rs3093024 and with  $r^2 = 0.89$ ) showed a substantial difference in binding of nuclear proteins between the two alleles (Supplementary Fig. 3b). Because the nucleotide immediately 3' of rs968334 was also found to be polymorphic through resequencing this region (Fig. 2a,b and Supplementary Fig. 3a), we analyzed the haplotype frequency of these two SNPs in 376 rheumatoid arthritis cases by direct sequencing and haplotype phasing. These two SNPs comprised three haplotypes (CA, CG and TG). We termed this 2-base-pair polymorphism CCR6 dinucleotide polymorphism (CCR6DNP) and thereafter analyzed it as a single, tri-allelic variant. When the binding of nuclear proteins was examined for these three alleles, higher binding was seen in the order of CA < CG < TG (Fig. 2c). Although no significant shift was detected in supershift assays using antibodies for nuclear proteins predicted by *in silico* procedures, including YY1 and LYF1 (data not

**Table 2 Association analysis of CCR6DNP and autoimmune diseases**

Disease	Number of subjects	Genotype count						Allele frequency			P value <sup>a</sup>
		CA/CA	CG/CA	CG/CG	TG/CA	TG/CG	TG/TG	CA	CG	TG	
Rheumatoid arthritis	2,297	29	161	398	208	897	604	0.09	0.40	0.50	$2.4 \times 10^{-9}$
Graves' disease	1,783	25	133	334	150	715	426	0.09	0.43	0.48	$2.4 \times 10^{-5}$
Crohn's disease	483	5	40	81	52	195	110	0.11	0.41	0.48	0.020
Controls	1,808	28	189	379	168	683	361	0.11	0.45	0.44	–

<sup>a</sup>P values to determine trends for genotype using the  $\chi^2$  test.

shown), this differential binding of unknown nuclear proteins should affect the transcriptional activity of each allele. We next performed reporter assays using oligonucleotides of these three alleles cloned into a plasmid vector containing the viral SV40 promoter. In parallel with the results from the gel shift assays, different enhancing activities were detected in the order of CA < CG < TG (Fig. 2d). Taken together, these results suggest that CCR6DNP is a strong candidate for a disease-causing variation that affects gene expression.

To analyze the effect of CCR6DNP on disease susceptibility and on phenotypes within individuals, we established a genotyping assay for CCR6DNP (Supplementary Fig. 4). We scored the alleles as 0, 1 and 2 for CA, CG and TG, respectively, according to the enhanced transcription observed in the *in vitro* assays. The diplotypes of individuals were in turn scored as 0, 1, 2, 3 and 4 by summing each individual's allele scores. When the expression of CCR6 in PSC cells ( $n = 57$ ) was regressed with this diplotype score for CCR6DNP, a significant correlation was observed ( $R^2 = 0.23$ ,  $P = 1.7 \times 10^{-4}$ ; Fig. 2e), supporting the regulatory effect of CCR6DNP. When the distribution of the diplotype scores for CCR6DNP was compared between 2,303 rheumatoid arthritis cases and 1,820 controls, a significant association was also observed ( $P = 2.4 \times 10^{-9}$  by trend test; Table 2 and Supplementary Table 1). Compared with the CA allele, the ORs of the other alleles demonstrated an identical trend order (CA, 1.00; CG, 1.14; and TG, 1.25) with those indicated in the *in vitro* assays, which supports the hypothesis that the triallelic variant is causal. Conditional regression analysis of the newly identified SNP with rs968334 did not indicate a significant independent association at a level of  $\alpha = 0.05$ , presumably because of the strong LD between the SNPs ( $D' = 1$ ) or because of inadequate statistical power due to the low minor-allele frequency of the newly identified SNP (minor allele frequency = 0.10). We also genotyped individuals with Graves' disease ( $n = 1,783$ ) and Crohn's disease ( $n = 483$ ); we found significant association of CCR6DNP with both Graves' disease ( $P = 2.4 \times 10^{-5}$ ) and Crohn's disease ( $P = 0.020$ ; Table 2).

To seek further association between the CCR6DNP genotype and phenotypes within individuals, we analyzed the serum level of IL-17 in rheumatoid arthritis cases. Among 451 cases examined, 28.5% showed detectable levels of IL-17 (here termed 'IL-17 active cases'). There was a significant association between the CCR6DNP genotype and the proportion of IL-17 active cases ( $P = 1.2 \times 10^{-3}$  by trend test; Fig. 2f). This association was still significant after adjustment for age and sex using a logistic regression model ( $P = 1.4 \times 10^{-3}$ ). No significant correlation was observed between CCR6DNP and the titer of IL-17 at  $\alpha = 0.05$ . We also analyzed the association between the CCR6DNP genotype and autoantibody positivity (anti-CCP antibodies and rheumatoid factors) in the same rheumatoid arthritis cases, but did not observe any significant association (Supplementary Fig. 5). These results suggest that CCR6DNP has a more direct link to the activation of Th17 cells and their secretion of IL-17 than in autoantibody response in rheumatoid arthritis.

The role of Th17 cells in autoimmune arthritis has been well demonstrated in SKG mice, an animal model for rheumatoid arthritis which results from a mutation in *Zap70* (ref. 8). In this model, Ccr6<sup>+</sup> Th17 cells are recruited into the inflamed joints by Ccl20 (a known ligand for Ccr6) that is produced by synovocytes and Th17 cells themselves. The arthritogenic role of Th17 cells in SKG mice is supported by the observation that the administration of blocking anti-Ccr6 antibodies substantially inhibits arthritis<sup>8</sup>. In humans, the majority of circulating Th17 cells express CCR6 (ref. 21), and its ligand, CCL20, is also detected in inflamed synovial tissues<sup>25</sup>. Preferential expression of CCR6 in synovial tissues from rheumatoid arthritis cases compared to those from osteoarthritis cases has been previously described<sup>25</sup> and was confirmed in our samples (Supplementary Fig. 6). Our observation that CCR6DNP is associated with rheumatoid arthritis susceptibility, as well as our detection of enhanced expression of CCR6 and the status of IL-17 in the serum of rheumatoid arthritis cases, implies that the same mechanism found in the mouse model might also underlie the pathogenesis of human rheumatoid arthritis.

The CCR6-CCL20-mediated migration of Th17 cells to inflamed tissues may also be important in other autoimmune diseases, as is implicated by the association of Graves' disease and Crohn's disease susceptibility to CCR6DNP observed in the present study. In Crohn's disease, a genetic marker in *FGFR1OP* (adjacent to *CCR6*) was also implicated in a meta-analysis of GWAS<sup>26</sup>, supporting the association of *CCR6* to disease. As several other genes implicated in Th17 function, such as *IL23R* and *STAT3*, have been associated with Crohn's disease susceptibility, Th17 cells are considered to play a substantial role in Crohn's disease<sup>27,28</sup>. In contrast, the lack of confirmatory evidence for an association of *IL23R* and *STAT3* in rheumatoid arthritis<sup>9–12</sup> implies that this pathway might be less important in rheumatoid arthritis as compared to Crohn's disease. Therefore, it is possible that the *CCR6* polymorphism could be involved in rheumatoid arthritis pathogenesis by influencing *CCR6*-expressing cell types other than Th17 cells. As enhanced expression of *CCR6* may differentially contribute to pathogenesis between different autoimmune diseases, studies of other autoimmune diseases are needed to clarify the etiological role of the *CCR6* polymorphism in autoimmunity.

## METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

**Accession numbers.** RefSeq, NM\_031409 and NM\_004367.

*Note: Supplementary information is available on the Nature Genetics website.*

## ACKNOWLEDGMENTS

We thank K. Shimada, Y. Hayashi, K. Kobayashi, M. Kitazato and other members of the Laboratory for Autoimmune Diseases, RIKEN and Y. Katagiri at Tokyo Women's Medical University, for their technical assistance. We also

thank the members of BioBank Japan and the Rotary Club of Osaka-Midosuji District 2660 Rotary International for supporting our study. This work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government. The replication study of rheumatoid arthritis was performed under the support of Genetics and Allied research in Rheumatoid Arthritis Networking (GARNET) consortium.

#### AUTHOR CONTRIBUTIONS

Y.K., Y.O. and K. Yamamoto, designed the study and drafted the manuscript. Y.O., A.T., T.T. and R.Y. analyzed the GWAS data. N.H. and M.K. performed the genotyping for the GWAS. Y.K. performed expression analysis of *CCR6* and functional analysis of *CCR6* polymorphisms. Y.K. and K.M. established the genotyping method for *CCR6DNP*. K.L., S.M. and H.Y. analyzed data for the first replication cohort of rheumatoid arthritis. C.T., K.O., T.M., R.Y. and F.M. analyzed the data for the second replication cohort of rheumatoid arthritis. Y.K. analyzed the data for the Graves' disease cohort. K. Yamazaki analyzed the data for the Crohn's disease cohort. T.F. and S.I. analyzed the data for the fourth control cohort. T.I. and K.I. analyzed *CCR6* expression in the synovial tissues. Y.K. and A.S. analyzed the sera of subjects with rheumatoid arthritis. M.K., N.K. and Y.N. contributed to overall GWAS study design.

#### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

1. Firestein, G.S. Evolving concepts of rheumatoid arthritis. *Nature* **423**, 356–361 (2003).
2. Newton, J.L., Harney, S.M., Wordsworth, B.P. & Brown, M.A. A review of the MHC genetics of rheumatoid arthritis. *Genes Immun.* **5**, 151–157 (2004).
3. Qin, S. *et al.* The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. *J. Clin. Invest.* **101**, 746–754 (1998).
4. Yamada, H. *et al.* Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. *Ann. Rheum. Dis.* **67**, 1299–1304 (2008).
5. Harrington, L.E. *et al.* Interleukin 17-producing CD4<sup>+</sup> effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat. Immunol.* **6**, 1123–1132 (2005).
6. Murphy, C.A. *et al.* Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. *J. Exp. Med.* **198**, 1951–1957 (2003).
7. Pernis, A.B. Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. *J. Intern. Med.* **265**, 644–652 (2009).
8. Hirota, K. *et al.* Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. *J. Exp. Med.* **204**, 2803–2812 (2007).
9. Plenge, R.M. *et al.* *TRAF1-C5* as a risk locus for rheumatoid arthritis—a genome-wide study. *N. Engl. J. Med.* **357**, 1199–1209 (2007).
10. Plenge, R.M. *et al.* Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat. Genet.* **39**, 1477–1482 (2007).
11. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* **447**, 661–678 (2007).
12. Gregersen, P.K. *et al.* *REL*, encoding a member of the NF- $\kappa$ B family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat. Genet.* **41**, 820–823 (2009).
13. Price, A.L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat. Genet.* **38**, 904–909 (2006).
14. Yamaguchi-Kabata, Y. *et al.* Japanese population structure, based on SNP genotypes from 7,003 individuals compared to other ethnic groups: effects on population-based association studies. *Am. J. Hum. Genet.* **83**, 445–456 (2008).
15. Devlin, B., Roeder, K. & Wasserman, L. Genomic control, a new approach to genetic-based association studies. *Theor. Popul. Biol.* **60**, 155–166 (2001).
16. Remmers, E.F. *et al.* *STAT4* and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N. Engl. J. Med.* **357**, 977–986 (2007).
17. Kobayashi, S. *et al.* Association of *STAT4* with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. *Arthritis Rheum.* **58**, 1940–1946 (2008).
18. Lee, H.S. *et al.* Association of *STAT4* with rheumatoid arthritis in the Korean population. *Mol. Med.* **13**, 455–460 (2007).
19. Suzuki, A. *et al.* Functional haplotypes of *PADI4*, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. *Nat. Genet.* **34**, 395–402 (2003).
20. Stahl, E.A. *et al.* Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat. Genet.* advance online publication, doi:10.1038/ng.582 (9 May 2010).
21. Annunziato, F. *et al.* Phenotypic and functional features of human Th17 cells. *J. Exp. Med.* **204**, 1849–1861 (2007).
22. Haas, J.D. *et al.* CCR6 and NK1.1 distinguish between IL-17A and IFN- $\gamma$ -producing  $\gamma\delta$  effector T cells. *Eur. J. Immunol.* **39**, 3488–3497 (2009).
23. Schutyser, E., Struyf, S. & Van Damme, J. The CC chemokine CCL20 and its receptor CCR6. *Cytokine Growth Factor Rev.* **14**, 409–426 (2003).
24. Frazer, K.A. *et al.* A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–861 (2007).
25. Matsui, T. *et al.* Selective recruitment of CCR6-expressing cells by increased production of MIP-3  $\alpha$  in rheumatoid arthritis. *Clin. Exp. Immunol.* **125**, 155–161 (2001).
26. Barrett, J.C. *et al.* Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat. Genet.* **40**, 955–962 (2008).
27. Brand, S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. *Gut* **58**, 1152–1167 (2009).
28. Wang, K. *et al.* Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. *Am. J. Hum. Genet.* **84**, 399–405 (2009).



## ONLINE METHODS

**Samples enrolled in the study.** We enrolled 7,090 rheumatoid arthritis cases, 1,783 Graves' disease cases, 483 Crohn's disease cases and 21,712 unaffected controls through several medical institutes in Japan under the support of the BioBank Japan Project<sup>29</sup>, the University of Tokyo, Institute of Rheumatology Rheumatoid Arthritis (IORRA), Kyoto University and the GARNET consortium. All subjects were of Japanese origin and provided written informed consent. Details of the samples are summarized in **Supplementary Table 1** and **Supplementary Note**. This research project was approved by the ethical committees of the BioBank Japan Project, RIKEN, the University of Tokyo, Tokyo Women's Medical University and Kyoto University.

**Genotyping and quality control.** In the GWAS, 2,322 rheumatoid arthritis cases and 3,473 controls were genotyped using the Illumina Human610-Quad and Illumina Human 550v3 Genotyping BeadChips (Illumina), respectively. After the exclusion of samples with low call rates (<98%), SNPs with low call rates (<99%), non-autosomal SNPs and those SNPs not shared among cases and controls were also excluded.

We excluded closely related samples using identity by descent estimated by PLINK<sup>30</sup> version 1.06. For sample pairs in a first degree of kinship, we excluded the individual who was a control, or in cases where that had not uniquely been determined, the individual had lower call rate than the other. We next excluded samples who were outliers in terms of ancestries. We performed PCA for the genotype data of the samples along with European (CEU), African (YRI) and East-Asian (Japanese and Han Chinese, denoted JPT + CHB) individuals obtained from Phase II HapMap database (release 22)<sup>24</sup> using EIGENSTRAT<sup>13</sup> version 2.0. A PCA plot clearly separated the samples into three clusters, as previously indicated<sup>14</sup> (**Supplementary Fig. 1**). The concordance of the cluster between JPT + CHB individuals and our samples suggested that our samples had homogeneous ancestries. We visually excluded the samples who were estimated to be outliers.

We excluded SNPs with minor allele frequency less than 0.05 in either rheumatoid arthritis cases or controls, or with Hardy-Weinberg equilibrium  $P$  value<sup>31</sup>  $>10^{-6}$  in controls. Cluster plots of SNPs were checked by visual inspection, and SNPs with ambiguous calls were excluded. Finally, 393,217 SNPs for 2,303 rheumatoid arthritis cases and 3,380 controls were obtained. The genotyping methods for the replication studies are described in **Supplementary Table 1**.

**Association analysis.** The associations of the SNPs were tested with the Cochran-Armitage trend test. Combined analysis was performed with the Mantel-Haenszel method. Correction for potential population stratification was performed by the genomic control method<sup>15</sup> and by using the results of PCA<sup>13</sup> (see **Supplementary Note** for details).

**Replication study for previously reported rheumatoid arthritis susceptibility loci.** We evaluated the associations in previously reported rheumatoid arthritis susceptibility loci<sup>9-12,16-19,32-39</sup> using the samples in our GWAS (2,303 rheumatoid arthritis cases and 3,380 controls) and the controls in the first replication study (15,873 controls). We imputed the SNPs that were not genotyped using MACH 1.0 (see URLs), with Phase II HapMap JPT + CHB individuals as references<sup>24</sup>. All the imputed SNPs demonstrated  $R^2$  values more than 0.95.

**Genotyping method for CCR6DNP.** The triallelic dinucleotide polymorphism in CCR6 (CCR6DNP) was genotyped using two sets of TaqMan MGB probes (**Supplementary Table 5**). Approximately 4 ng DNA was amplified in a 5  $\mu$ l reaction mixture comprising 200 nM each of probe and 900 nM each of primer in TaqMan genotyping master mix (Applied Biosystems). After denaturation at 95 °C for 10 min, 50 cycles of denaturation at 95 °C for 15 s and annealing and extension at 58 °C for 1 min were performed. The results for the reactions of two probe sets were analyzed together and the genotype of each sample was determined by an algorithm as shown in **Supplementary Figure 4**. The genotypes of 376 individuals completely matched (100%) those obtained by direct sequencing.

**DNA resequencing.** Unknown genetic variants were revealed by directly sequencing of the DNA of 24 individuals affected with rheumatoid

arthritis. DNA fragments were amplified for sequencing with appropriate primers and were purified using a MultiScreen PCR filter plate (Millipore). The amplified DNAs were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and signals were detected using an Applied Biosystems ABI 3700 DNA Analyzer.

**Quantification of gene expression.** EBV-transformed lymphoblastoid cell lines ( $n = 57$ ) were established by the Pharma SNP Consortium (PSC, Tokyo, Japan) using peripheral blood lymphocytes of Japanese healthy individuals. Cells were incubated for 2 h in medium alone (RPMI 1640 medium containing 10% FBS albumin, 1% penicillin and 1% streptomycin) or with 100 ng/ml PMA. Conditions for cell stimulation were optimized before the experiment as previously described<sup>40</sup>. Cells were then harvested and total RNA was isolated using an RNeasy Mini Kit (Qiagen) with DNase treatment. Total RNA from synovial tissues was isolated from rheumatoid arthritis cases ( $n = 74$ ) and osteoarthritis cases ( $n = 8$ ) who underwent total knee replacement surgery. Total RNA (1  $\mu$ g) was reverse transcribed using TaqMan Gold RT-PCR reagents with random hexamers (Applied Biosystems). Real-time quantitative PCR was performed in triplicate using an ABI PRISM 7900 and TaqMan gene expression assays (Applied Biosystems). Specific probes for each transcript of CCR6 were used: Hs00171121\_m1 was used for CCR6-a (NM\_031409) and a custom-made probe set was used for CCR6-b (NM\_004367); both the custom probe and Hs00171121\_m1 were comprised of a minor groove binder probe (**Supplementary Table 5**). Possible contamination of DNA was excluded by performing PCR with total RNA without the reverse transcription step. The data were normalized to GAPDH levels. GUS and 18S rRNA levels were also evaluated for internal control, and similar results were obtained among the three probes.

**Correlation analysis between genotype and gene expression.** DNA was extracted from PSC cells and genotyped for the tag SNPs using TaqMan genotyping assays (Applied Biosystems). The levels of each transcript of CCR6 were regressed with the genotype in a linear model, assuming an additive effect of the allele. The correlation coefficients  $R^2$  were used for fine mapping of the correlation between SNP genotypes and CCR6 expression in this region. The significance of regression was tested by an  $F$  test.

**Electrophoretic mobility shift assay (EMSA).** EMSA and preparation of nuclear extract from PSC cells were performed as previously described<sup>41</sup>. Following stimulation with 50 ng/ml PMA for 2 h, cells were collected and lysed in Buffer A (20 mM HEPES at pH 7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA at pH 8.0, 1 mM DTT, 0.1% NP-40 detergent and a protease inhibitor cocktail). The cells were then incubated on ice for 10 min, centrifuged, and the pellets were resuspended in Buffer B (which contains Buffer A with 500 mM NaCl). Following incubation on ice for 30 min and centrifugation, the supernatant fraction containing nuclear proteins was collected. Oligonucleotides (31 base pairs) were designed that corresponded to genomic sequences surrounding the SNPs of interest. Single-stranded oligonucleotide probes were labeled using a Biotin 3' End DNA Labeling Kit (Pierce Biotechnology), and sense and antisense oligonucleotides were then annealed. DNA-protein interactions were detected by using a LightShift Chemiluminescent EMSA kit (Pierce Biotechnology) according to the manufacturer's instructions. The DNA-protein complexes were separated on a non-denaturing 5% polyacrylamide gel in 1 $\times$  TBE (Tris-borate-EDTA) running buffer for 70 min at 150 V. The gel was transferred to a nitrocellulose membrane, and signals were detected using a LAS-3000 lumino image analyzer (Fujifilm).

**In silico prediction of transcription factor binding site.** DNA sequences around each allele of the CCR6DNP were evaluated for the potential of transcriptional factor binding using Match software version 1.0 (see URLs). This software uses a library of mononucleotide weight matrices from TRANSFAC 6.0 (see URLs).

**Luciferase assay.** Oligonucleotides (31 base pairs) were generated using the allelic sequences of nucleotides surrounding CCR6DNP (**Supplementary Table 6**). A single copy of the oligonucleotide was cloned into the pGL3-Promoter Vector (Promega) at the M $\mu$ I and BglII restriction enzyme binding sites. Each construct was then transformed into *Escherichia coli* DH5 $\alpha$  (Toyobo). These plasmids were purified using a HiSpeed Plasmid Midi Kit (Qiagen)



after confirmation of the sequence. HEK293A cells (Invitrogen) were grown in Dulbecco's modified Eagle medium (Sigma) supplemented with 10% FBS and antibiotics. Cells ( $n = 2 \times 10^5$ ) were transfected with 0.8  $\mu\text{g}$  constructs and 0.2  $\mu\text{g}$  pRL-TK vector (an internal control for transfection efficiency) using the TransFast Transfection Reagent (Promega). After 20 h, 100 ng/ml PMA was added to the medium. Following an additional incubation for 4 h, cells were collected and luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega) and a Lumat LB 9507 Ultra Sensitive Tube Luminometer (Berthold Technologies). Each experiment was independently repeated three times and octuplicate samples were assayed each time.

**Measurement of autoantibodies and IL-17.** Anti-citrullinated peptide antibodies were measured using a MESACUP CCP test (Medical & Biological Laboratories) according to the manufacturer's instructions. Rheumatoid factors were measured by ELISA as previously described<sup>42</sup>. Human IL-17 was measured by ELISA, with a detection limit of 4 pg/ml (eBioscience).

**URLs.** MACH, <http://www.sph.umich.edu/csg/abecasis/mach/>; Match software, <http://www.gene-regulation.com/>; TRANSFAC, <http://www.biobase-international.com/>.

29. Nakamura, Y. The BioBank Japan Project. *Clin. Adv. Hematol. Oncol.* **5**, 696–697 (2007).
30. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
31. Wigginton, J.E., Cutler, D.J. & Abecasis, G.R. A note on exact tests of Hardy-Weinberg equilibrium. *Am. J. Hum. Genet.* **76**, 887–893 (2005).
32. Kochi, Y. *et al.* A functional variant in *FCRL3*, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. *Nat. Genet.* **37**, 478–485 (2005).
33. Tokuhira, S. *et al.* An intronic SNP in a *RUNX1* binding site of *SLC22A4*, encoding an organic cation transporter, is associated with rheumatoid arthritis. *Nat. Genet.* **35**, 341–348 (2003).
34. Suzuki, A. *et al.* Functional SNPs in *CD244* increase the risk of rheumatoid arthritis in a Japanese population. *Nat. Genet.* **40**, 1224–1229 (2008).
35. Raychaudhuri, S. *et al.* Common variants at *CD40* and other loci confer risk of rheumatoid arthritis. *Nat. Genet.* **40**, 1216–1223 (2008).
36. Thomson, W. *et al.* Rheumatoid arthritis association at 6q23. *Nat. Genet.* **39**, 1431–1433 (2007).
37. Shimane, K. *et al.* The association of a nonsynonymous single-nucleotide polymorphism in *TNFAIP3* with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. *Arthritis Rheum.* **62**, 574–579 (2010).
38. Raychaudhuri, S. *et al.* Genetic variants at *CD28*, *PRDM1* and *CD2/CD58* are associated with rheumatoid arthritis risk. *Nat. Genet.* **41**, 1313–1318 (2009).
39. Okada, Y. *et al.* *SLC22A4* polymorphism and rheumatoid arthritis susceptibility: a replication study in a Japanese population and a meta-analysis. *J. Rheumatol.* **35**, 1723–1728 (2008).
40. Nishimoto, K. *et al.* Association study of *TRAF1-C5* polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese. *Ann. Rheum. Dis.* **69**, 368–373 (2010).
41. Aikawa, Y., Yamamoto, M., Yamamoto, T., Morimoto, K. & Tanaka, K. An anti-rheumatic agent T-614 inhibits NF- $\kappa$ B activation in LPS- and TNF- $\alpha$ -stimulated THP-1 cells without interfering with I $\kappa$ B $\alpha$  degradation. *Inflamm. Res.* **51**, 188–194 (2002).
42. Shimane, K. *et al.* A single nucleotide polymorphism in the *IRF5* promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population. *Ann. Rheum. Dis.* **68**, 377–383 (2009).

